Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investment Corp. investor Brady Priest filed a Form 144 covering proposed sales of common stock. The notice lists two planned sales related to stock option exercises dated August 7, 2026, for 79,349 and 362,252 shares. It also reports a prior sale of 98,039 common shares on May 13, 2026 for $345,107.08, routed through Morgan Stanley Smith Barney LLC Executive Financial Services.
Clover Health Investments reported results for the quarter ended June 30, 2026. Total revenues were $743.2 million, up 55.6% year-over-year, driven by Medicare Advantage growth. GAAP net income was $28.0 million, compared with a net loss of $10.6 million a year earlier, and diluted earnings per share were $0.05.
Average Medicare Advantage membership reached 156,840, up 48.7%, with 157,309 insurance members at June 30, 2026. Consolidated Gross profit (non-GAAP) was $153.0 million, up 53.6%, and Adjusted EBITDA was $40.9 million, up 139.2% year-over-year. Insurance Benefits Expense Ratio was 87.6%, an 80-basis-point improvement.
The company raised full-year 2026 guidance to total revenues of $2.92–$3.00 billion, Consolidated Gross profit of $525–$555 million, Adjusted EBITDA of $70–$85 million, GAAP net income of $20–$35 million, and average Medicare Advantage membership of 156,000–158,000. Cash, cash equivalents, and investments totaled $443.0 million at June 30, 2026.
Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026, reported as a sale in the open market or a private transaction at a $4.51 weighted average price, with individual prices from $4.46 to $4.59, pursuant to a 10b5-1 plan adopted on March 13, 2026. Following this sale, she directly holds 1,505,522 shares.
Clover Health Investments (CLOV) insider Karen Soares filed to sell up to 51,700 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of $238,854.00. The securities relate to Restricted Stock Units granted on 03/15/2026, with additional sales already made in the past three months.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 4,839 shares of Class A Common Stock on July 17, 2026, at a $4.53 weighted average price, in multiple trades between $4.35 and $4.63 per share, under a Rule 10b5-1 trading plan adopted March 12, 2026. Following this sale, Reynoso directly holds 2,814,640 shares of Class A Common Stock.
Jamie Reynoso reports an intention under Rule 144 to sell up to 4,839 shares of CLOV common stock through Morgan Stanley Smith Barney LLC, with an indicated value of $21,291.60. The notice also lists multiple prior common-stock sales between June 11 and July 15, 2026, some under 10b5-1 plans.
Clover Health Investments, Corp. reports a cybersecurity incident involving anomalous login activity detected on July 4, 2026 on certain information systems. An investigation, supported by third-party cybersecurity experts, determined that a threat actor accessed three non-managerial health plan employee accounts through social engineering.
The affected accounts were used for member visit-scheduling and broker-facing sales functions and had access to some personally identifiable information and protected health information, but no access to corporate financial or claims systems. Clover Health states that its rapid response contained and terminated the unauthorized access and, based on information currently available, it does not believe the incident has had, or is reasonably likely to have, a material impact on its business, financial condition, or results of operations. The company has notified law enforcement, is further hardening its IT environment, and will provide required notifications, including to impacted members, once its assessment of the scope and nature of any data access is complete.
Clover Health Investments CEO Andrew Toy reported a required sale of 62,711 Class A shares at a weighted average price of $4.67 per share to cover tax withholding from the vesting of 6.25% of RSUs originally granted on October 15, 2024. The company’s equity plan mandates these sell to cover trades, so they were not discretionary. After the sale, Toy directly holds 9,547,114 shares. Remaining RSUs vest in equal 6.25% quarterly installments through October 15, 2028, subject to continued service.
Clover Health Investments insider activity shows Wai Conrad, CEO of Counterpart Health, sold 24,215 Class A shares on July 15, 2026 at a weighted average $4.67, with prices from $4.67 to $4.73, solely to cover tax withholding on vesting of 6.25% of RSUs granted October 15, 2024. These mandated “sell to cover” trades under the company’s equity incentive plans are not discretionary. Afterward he held 1,145,699 shares directly and 1,390,056 shares indirectly through a family trust where he is co‑trustee, while the remaining RSUs vest quarterly in 6.25% installments through October 15, 2028.